TW201615224A - 消化系統疾病用藥臨床新應用 - Google Patents

消化系統疾病用藥臨床新應用 Download PDF

Info

Publication number
TW201615224A
TW201615224A TW104134963A TW104134963A TW201615224A TW 201615224 A TW201615224 A TW 201615224A TW 104134963 A TW104134963 A TW 104134963A TW 104134963 A TW104134963 A TW 104134963A TW 201615224 A TW201615224 A TW 201615224A
Authority
TW
Taiwan
Prior art keywords
cancer
drug
drugs
group
digestive
Prior art date
Application number
TW104134963A
Other languages
English (en)
Inventor
陳丘泓
莊秀美
蕭乃文
梁瑞岳
筱彤 陳
Original Assignee
朗齊生物醫學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朗齊生物醫學股份有限公司 filed Critical 朗齊生物醫學股份有限公司
Publication of TW201615224A publication Critical patent/TW201615224A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本發明提供多種消化系統疾病用藥的新臨床之應用。該多種消化系統疾病用藥皆是經過衛生署通過核准上市的消化系統疾病用藥。本發明提供多種消化系統疾病用藥有效的抑制不同類型的癌細胞。

Description

消化系統疾病用藥臨床新應用
本發明係為多種消化系統疾病用藥的新適應症之應用，尤其該多種藥物為通過臨床實驗且具有抑制多種癌症之用途。
癌症長期高居全球死因之首，且罹患癌症人數更是逐年攀升，因此治療癌症儼然成為重要的課題。癌症的治療可區分為手術治療、放射線治療、化學治療及標靶治療。
一般來說，癌症藥物治療無論是化學治療或標靶治療，目的多是讓癌細胞無法複製、分裂，來阻斷腫瘤的蔓延擴張。在臨床治療選擇上，通常會結合一到數種化療藥物以及標靶治療，希望能藉由不同機制來殺死癌細胞以提高治療效果，但事實上，還是常遇到患者對於治療藥物的反應不佳。進一步，許多癌細胞相繼產生抗藥性，使藥物的使用成效大幅降低，最終導致癌症治療失敗。
消化系统是多細胞生物用以進食、消化食物、獲取能量和營養、排泄剩餘废物的一组器官，其主要功能為攝取、消化、吸收、同化和排泄。其中有關排泄的部分，也可歸類到排泄系統的一部分。下痢、腹瀉、乳糖不耐症、便祕、打隔、胃灼熱、食物中毒、嘔吐、噁心、脹氣、腸胃潰瘍、膽結石、B型肝炎、C型肝炎、胃食道 逆流、消化行潰瘍、大腸憩室症等皆屬於消化道疾病。
發明人依據長年的研究經驗，人類的癌症細胞常常有與正常細胞具有不同的表現性狀，型態上的差異或是作用機轉的變化或許也有可能被視為一種外來的侵入者，而每一種癌症細胞所在的位置不同，變異的狀態又與所處的環境有關，因此，第一個提出使用消化系統疾病用藥抑制癌症細胞的發明概念並且進行實驗。
相對的，在這些已經使用數十年消化系統疾病用藥，是早已被FDA所認可的用藥，具有大量藥物機轉及人體研究成果資料，因此，若應用在癌症方面，這項新發展會更省時、減少成本，也能和其他治療方式結合來提高效果。目前尚未有任何研究針對本發明所使用之藥物，進行癌症治療研究。
儘管如此，藥物開發依然是重要的醫學議題，必須經過繁複的臨床前試驗才能進入臨床試驗，根據統計，平均每一萬個新藥約只有五個能夠進入第一期臨床試驗。此外，除了藥物本身是否能大量製造的難題外，還需克服藥物安全性、病人篩選、試用劑量等問題，即便藥物已經通過FDA的核准並上市，亦有可能因上市後於人體發現不良反應而強制下架回收，由此可見藥物開發具有一定的困難程度。
為解決上述的問題，本發明係針對通過臨床實驗的多種藥物進行新適應症的研發，而達到老藥新用的目標。
經過實驗設計結果顯示消化系統疾病用藥對正常細胞沒有或僅有微小的毒性，但至於消化系統疾病用藥在正常細胞與腫 瘤細胞之間是否具有選擇性的影響，還待更多的研究釐清，而且並非所有的消化系統疾病用藥在相同的條件下均能有效的抑制腫瘤細胞，需要有許多的問題進行克服。
名詞定義
消化系統疾病用藥依據藥物的結構可以分為十二大類，包含止吐劑、止瀉劑整腸劑、抗痙攣劑、抗腹瀉劑、其他消化系統用藥、制酸劑、制酸劑抗發脹劑、呼吸興奮劑、消化性潰瘍治療劑、健胃消化劑利膽劑、催吐劑鎮吐劑鎮暈劑、瀉劑所組成群組與其他類。
抗痙攣劑，用於平滑肌收縮，尤其是在胃腸道的管狀器官。其效果是防止胃、腸或膀胱的痙攣。雙環錐林(Dicycloverine)、及天仙子胺這兩種是具有抗膽鹼劑作用的解痙藥。這兩種藥物具有一般的副作用，並且可能惡化胃食管反流病出。
制酸劑，英文名Antacids，內含鋁或(及)鎂之化合物為主，主要利用其中和胃酸的能力，用以緩解或預防因為胃酸過多所引起的心口灼熱感、胃脹氣或消化不良的症狀，也可用來治療或預防潰瘍的發生。制酸劑常見的藥物為內含鋁或(及)鎂之化合物為主，主要利用其中和胃酸的能力，用以緩解或預防因為胃酸過多所引起的心口灼熱感、胃脹氣或消化不良的症狀，也可用來治療或預防潰瘍的發生。制酸劑的主要藥理功效為：緩解或預防因為胃酸過多所引起的心口灼熱感、胃脹氣或消化不良的症狀，也可用來治療或預防潰瘍的發生，或中和胃酸。
呼吸興奮用藥，呼吸興奮屬於中樞興奮藥，主要通過直接興奮延髓呼吸中樞，也可通過刺激頸動脈體和主動脈體的化學感 受器反射性的興奮呼吸中樞，使呼吸加深加快，通氣量增加，提高了血中氧分壓，降低了血中二氧化碳分壓。提高呼吸中樞對二氧化碳的敏感性，在呼吸中樞處於抑制狀態時興奮作用尤為明顯。
消化性潰瘍是指一群由胃酸或蛋白畊等攻擊因子所造成上消化道形成潰瘍性變化的疾病總稱。目前學者們大多支持重要假說，就是攻擊因子與胃腸黏膜的防禦因子失衡所致。廣義而言，攻擊因子包括：(1)胃酸及蛋白，(2)藥物，(3)酒精，(4)抽煙，(5)膽汁逆流，(6)細菌，如幽門螺旋桿菌；防禦因子則包括：1黏膜表面黏液及碳酸氫離子的分泌，2.表面細胞的屏障，3.黏膜細胞的更新，4.黏膜層血流的供應，5.內因性前列腺的合成。其中攻擊因子亦會直接或間接影響防禦因子，而依發生的部位來分類，主要包括(1)十二指腸潰瘍和(2)胃潰瘍。
胃潰瘍好發年紀約比十二指腸潰瘍多出10-20歲，以60-70歲的年齡較常見，男女發生比率略同，相對於胃酸分泌過多為十二指腸潰瘍之致病主因，胃潰瘍患者的胃酸分泌大多數為正常或較少，而胃泌素則呈偏高的狀態，胃的排空速度較慢，且胃黏膜呈現不同程度的慢性胃炎及胃黏膜萎縮的現象。大多數學者都同意胃潰瘍的發生原因為多因性，偏重於一些黏膜防衛機轉的缺陷，至於幽門螺旋桿菌在胃潰瘍患者陽性率約65-80%，高於一般人，但低於十二指腸潰瘍患者的陽性率，相關性較低，目前治療方面仍建議作幽門螺旋桿菌之清除。臨床症狀方面，以上腹痛最為常見，但相較於十二指腸潰瘍的痛，則較不典型，若出現胃出血或穿孔的情況，其引起死亡率的機會，亦較十二指腸潰瘍為高。內視鏡用於胃潰瘍患者之診斷，除了可 直接觀查潰瘍之大小、形狀、部位及慢性炎症的變化，亦可作組織切片生檢，確定良性或惡性潰瘍，及檢查幽門螺旋桿菌之存在與否。至於治療方面，如同十二指腸潰瘍，包括個人及家族罹患惡性腫瘤的情形，建議病人避免使用加重潰瘍的食物及藥物；如煙、酒及止痛藥(NSAID)等，胃潰瘍治療仍以內科藥物為主，與十二指腸潰瘍之藥物相通，但似乎胃潰瘍的癒合較十二指腸潰瘍為慢，且較大的潰瘍也須花費較長的時間癒合，呈陽性之幽門螺旋桿菌檢驗結果，仍建議作幽門螺旋桿菌之清除。
一種制備抑制癌症之醫藥組合物之方法，其中該醫藥組合物係為一消化疾病藥物。
本發明一實施例中，其中該消化疾病藥物係選自由止吐劑、止瀉劑整腸劑、抗痙攣劑、抗腹瀉劑、其他消化系統用藥、制酸劑、制酸劑抗發脹劑、呼吸興奮劑、消化性潰瘍治療劑、健胃消化劑利膽劑、催吐劑鎮吐劑鎮暈劑、瀉劑所組成群組之消化疾病藥物。
本發明一實施例中，其中該抗痙攣劑係選自由Moxonidine、Moexipril HCl、Alverine Citrate及Camylofin Chlorhydrate所組成之藥物。
本發明一實施例中，其中該制酸劑係為Esomeprazole magnesium(Nexium)或/和Roxatidine acetate HCl藥物。
本發明一實施例中，其中該該呼吸興奮劑係Sorbitol(Glucitol)藥物。
本發明一實施例中，其中該消化性潰瘍治療劑係選自由Danofloxacin Mesylate和/或Bentiromide所組成之藥物。
本發明一實施例中，其中該胃潰瘍用藥系為Troxipide藥物。
本發明一實施例中，其中該急性腹痛藥物系為Rofecoxib之藥物。
本發明一實施例中，其中該癌症係選自由肺癌、腸道癌、大腸直腸癌、前列腺癌、肝癌、膀胱癌、子宮頸癌、乳癌及血癌所組成之群組。
本發明一實施例中，其中該藥物的有效劑量濃度為每日20mg/kg~500mg/kg。
現今癌症藥物費用動輒上萬至數百萬元，若未來更進一步證實消化系統疾病用藥對腫瘤的療效，對於無法負擔昂貴治療的患者們，這些便宜而歷史悠久的藥物，會是帶來健康的新希望。
第一圖顯示本發明消化系統疾病用藥應用於抑制癌細胞分析結果。
建立細胞株
請參考表一，將不同癌症類型的細胞株進行繼代培養，計算細胞數目後，回種2x106細胞數，然後加入培養該細胞株之培養液補至體積為10ml，繼續培養2-3天。之後將細胞計數，並分裝至96孔盤，其中每孔的細胞數目固定為3000顆，且體積為100ul。
IC50即半抑制濃度(或稱半抑制率)。在間接競爭ELISA標準曲線中是一個非常重要的資料，標準曲線是一個S型曲線。ICELISA中，不添加藥物的對照組的OD值定為B0，添加了藥物的實驗組的OD值為B，B/B0%就叫做結合率，在結合率為50%時所對應的藥物的濃度就叫做IC50。一般IC50的數值越小表示藥物的抑制效果越強。
細胞存活分析方法
將96孔盤中原有的培養液吸掉，每孔加入濃度10um、體積100ul的市售藥物，放置72小時後，每孔再加入100ul已稀釋的WST-1試劑，該稀釋比例為培養液與WST-1原液的體積比為9：1，最後每個孔盤的總體積為200ul，然後將96孔盤放置於37度30~90分鐘，利用elisa reader於OD450偵測吸光值，並計算各癌症細胞株之存活率。
消化系統疾病用藥應用於抑制癌細胞分析結果
消化系統疾病用藥分為九大類，分別為抗感染用藥、鎮咳用藥、祛痰用藥、平喘用藥、呼吸興奮用藥、感冒用藥、急性支氣管炎用藥、慢性支氣管炎用藥、支氣管哮喘用藥類抑制癌細胞生長的效果。
實驗結果明顯的顯示有許多的消化系統疾病用藥並無法有效的抑制癌症的細胞的生長(表二)。
而相對的各種的消化系統疾病用藥分子對於各種癌症細胞的抑制效果也不盡相同(圖一)，經過發明人實驗結果，證實消 化系統疾病用藥藥物Esomeprazole magnesium(Nexium)、Roxatidine acetate HCl、Moxonidine、Moexipril HCl、Sorbitol(Glucitol)、Rofecoxib(Vioxx)、Alverine Citrate、Danofloxacin Mesylate、Troxipide、Bentiromide、Camylofin Chlorhydrate等藥物對於不同的癌症細胞有明顯的抑制效果。(表三)
重複性實驗
依據表三所示結果，針對對癌症細胞株有效之藥物進行重覆性實驗，其結果如表四所示。
上列詳細說明係針對本發明之一可行實施例之具體說明，惟該實施例並非用以限制本發明之專利範圍，凡未脫離本發明技藝精神所為之等效實施或變更，均應包含於本發明之專利範圍中。

Claims (9)

  1. 一種製備抑制癌症之醫藥組合物之方法，其中該醫藥組合物係為有效濃度的一消化疾病藥物及一藥物可接受的鹽類所組成。
  2. 如申請專利範圍第1項所述之方法，其中該消化疾病藥物係選自由抗痙攣劑、抗腹瀉劑、制酸劑、呼吸興奮劑、胃潰瘍治療劑、急性腹痛所組成群組之消化疾病藥物。
  3. 如申請專利範圍第2項所述之方法，其中該抗痙攣劑係選自由Moxonidine、Moexipril HCl、Alverine Citrate及Camylofin Chlorhydrate所組成之藥物。
  4. 如申請專利範圍第2項所述之方法，其中該制酸劑係為Esomeprazole magnesium(Nexium)或/和Roxatidine acetate HCl藥物。
  5. 如申請專利範圍第2項所述之方法，其中該呼吸興奮劑係Sorbitol(Glucitol)藥物。
  6. 如申請專利範圍第2項所述之方法，其中該胃潰瘍治療劑係為Danofloxacin Mesylate和/或Bentiromide。
  7. 如申請專利範圍第2項所述之方法，其中該胃潰瘍用藥系為Troxipide藥物。
  8. 如申請專利範圍第2項所述之方法，其中該急性腹痛藥物系為Rofecoxib之藥物。
  9. 如申請專利範圍第1項所述之方法，其中該癌症係選自由肺癌、腸道癌、大腸直腸癌、前列腺癌、肝癌、膀胱癌、子宮頸癌、腎臟癌及乳癌所組成之群組。
TW104134963A 2014-10-24 2015-10-23 消化系統疾病用藥臨床新應用 TW201615224A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24

Publications (1)

Publication Number Publication Date
TW201615224A true TW201615224A (zh) 2016-05-01

Family

ID=55760314

Family Applications (21)

Application Number Title Priority Date Filing Date
TW104134936A TWI621434B (zh) 2014-10-24 2015-10-23 千憂解藥物應用於癌症治療
TW104134964A TW201615225A (zh) 2014-10-24 2015-10-23 內分泌疾病用藥臨床新應用
TW104134959A TW201615223A (zh) 2014-10-24 2015-10-23 驅蟲藥臨床新應用
TW104134956A TW201615196A (zh) 2014-10-24 2015-10-23 山喜多藥物應用於癌症治療
TW104134924A TW201615218A (zh) 2014-10-24 2015-10-23 心血管疾病藥物臨床新應用
TW104134961A TW201615193A (zh) 2014-10-24 2015-10-23 帕羅西汀藥物應用於癌症治療
TW104134966A TW201615194A (zh) 2014-10-24 2015-10-23 氨苯蝶啶藥物應用於癌症治療
TW104134960A TW201615191A (zh) 2014-10-24 2015-10-23 氨氯地平藥物應用於癌症治療
TW104134908A TWI672150B (zh) 2014-10-24 2015-10-23 抗生素藥物臨床新應用
TW104134928A TW201615197A (zh) 2014-10-24 2015-10-23 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療
TW104134952A TW201615221A (zh) 2014-10-24 2015-10-23 炎症用藥臨床新應用
TW104134942A TW201615195A (zh) 2014-10-24 2015-10-23 阿那格雷藥物應用於癌症治療
TW104134944A TW201615219A (zh) 2014-10-24 2015-10-23 呼吸系統疾病用藥臨床新應用
TW104134950A TWI663969B (zh) 2014-10-24 2015-10-23 莫諾苯宗藥物應用於癌症治療
TW104134933A TWI652060B (zh) 2014-10-24 2015-10-23 阿折地平藥物應用於癌症治療
TW104134945A TW201615188A (zh) 2014-10-24 2015-10-23 奈必洛爾藥物應用於癌症治療
TW104134963A TW201615224A (zh) 2014-10-24 2015-10-23 消化系統疾病用藥臨床新應用
TW104134946A TWI663984B (zh) 2014-10-24 2015-10-23 神經疾病用藥臨床新應用
TW104134965A TW201615226A (zh) 2014-10-24 2015-10-23 代謝性疾病藥物臨床新應用
TW104134954A TW201615222A (zh) 2014-10-24 2015-10-23 免疫疾病用藥臨床新應用
TW104134940A TW201615186A (zh) 2014-10-24 2015-10-23 脫克鈣藥物應用於癌症治療

Family Applications Before (16)

Application Number Title Priority Date Filing Date
TW104134936A TWI621434B (zh) 2014-10-24 2015-10-23 千憂解藥物應用於癌症治療
TW104134964A TW201615225A (zh) 2014-10-24 2015-10-23 內分泌疾病用藥臨床新應用
TW104134959A TW201615223A (zh) 2014-10-24 2015-10-23 驅蟲藥臨床新應用
TW104134956A TW201615196A (zh) 2014-10-24 2015-10-23 山喜多藥物應用於癌症治療
TW104134924A TW201615218A (zh) 2014-10-24 2015-10-23 心血管疾病藥物臨床新應用
TW104134961A TW201615193A (zh) 2014-10-24 2015-10-23 帕羅西汀藥物應用於癌症治療
TW104134966A TW201615194A (zh) 2014-10-24 2015-10-23 氨苯蝶啶藥物應用於癌症治療
TW104134960A TW201615191A (zh) 2014-10-24 2015-10-23 氨氯地平藥物應用於癌症治療
TW104134908A TWI672150B (zh) 2014-10-24 2015-10-23 抗生素藥物臨床新應用
TW104134928A TW201615197A (zh) 2014-10-24 2015-10-23 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療
TW104134952A TW201615221A (zh) 2014-10-24 2015-10-23 炎症用藥臨床新應用
TW104134942A TW201615195A (zh) 2014-10-24 2015-10-23 阿那格雷藥物應用於癌症治療
TW104134944A TW201615219A (zh) 2014-10-24 2015-10-23 呼吸系統疾病用藥臨床新應用
TW104134950A TWI663969B (zh) 2014-10-24 2015-10-23 莫諾苯宗藥物應用於癌症治療
TW104134933A TWI652060B (zh) 2014-10-24 2015-10-23 阿折地平藥物應用於癌症治療
TW104134945A TW201615188A (zh) 2014-10-24 2015-10-23 奈必洛爾藥物應用於癌症治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
TW104134946A TWI663984B (zh) 2014-10-24 2015-10-23 神經疾病用藥臨床新應用
TW104134965A TW201615226A (zh) 2014-10-24 2015-10-23 代謝性疾病藥物臨床新應用
TW104134954A TW201615222A (zh) 2014-10-24 2015-10-23 免疫疾病用藥臨床新應用
TW104134940A TW201615186A (zh) 2014-10-24 2015-10-23 脫克鈣藥物應用於癌症治療

Country Status (9)

Country Link
US (7) US20170304286A1 (zh)
EP (3) EP3210604B1 (zh)
JP (1) JP6539345B2 (zh)
KR (1) KR102490334B1 (zh)
CN (3) CN107106523A (zh)
AU (2) AU2015335391B2 (zh)
ES (2) ES2973279T3 (zh)
TW (21) TWI621434B (zh)
WO (21) WO2016062266A1 (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101384172B (zh) 2005-12-28 2014-05-07 沃泰克斯药物股份有限公司 N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式
ES2973279T3 (es) * 2014-10-24 2024-06-19 Launxp Biomedical Co Ltd Usos de medicamento de duloxetina·HCl en la preparación de una composición farmacéutica para el tratamiento de cáncer
US11324746B2 (en) 2014-12-22 2022-05-10 Arovella Therapeutics Limited Use of anagrelide for treating cancer
WO2017116049A1 (ko) * 2015-12-31 2017-07-06 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (zh) * 2016-06-15 2016-11-09 中南大学湘雅医院 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用
US10688086B2 (en) * 2016-10-19 2020-06-23 Germark Biotechnology Co., Ltd Method for treating cancer with dihydropyridine calcium antagonist
CN108066345A (zh) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 一种具有抗肿瘤作用的化合物
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US20200179404A1 (en) * 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
US20200129492A1 (en) * 2017-07-03 2020-04-30 Menri Group Ltd. Treatment of cancer with dihydropyridines
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
KR101933805B1 (ko) 2017-10-17 2018-12-28 성균관대학교산학협력단 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물
CN108186652A (zh) * 2017-12-28 2018-06-22 深圳大学 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用
CA3089712A1 (en) 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
US11931366B2 (en) * 2018-04-19 2024-03-19 Washington University Compositions and methods of use thereof for treatment of proteinopathies
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
FR3090084B1 (fr) 2018-12-18 2023-10-13 Securengy Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent.
WO2020132253A1 (en) * 2018-12-19 2020-06-25 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
CN113924090A (zh) * 2019-04-04 2022-01-11 大邱庆北尖端医疗产业振兴财团 用于预防或治疗癌症的包含曲美布汀或其药学上可接受的盐作为活性成分的药物组合物
US20220202771A1 (en) * 2019-04-05 2022-06-30 University Of North Texas Health Science Center At Fort Worth Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging
CA3136353A1 (en) * 2019-04-11 2020-10-15 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (zh) * 2019-05-31 2019-08-30 天津科技大学 一种噻吨溴类化合物的应用
CN110742890A (zh) * 2019-10-24 2020-02-04 暨南大学 洛美利嗪在制备抗结肠癌药物中的应用
CN110840887A (zh) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 三氯苯达唑在制备治疗乳腺癌的药物中的应用
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN111067899B (zh) * 2020-01-08 2021-03-05 温州医科大学 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (zh) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途
CN111557941A (zh) * 2020-06-15 2020-08-21 浙江大学 Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用
CN111848717A (zh) * 2020-08-07 2020-10-30 四川大学 靶向调控线粒体能量代谢的化合物及其应用和药物
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN112336725A (zh) * 2020-12-11 2021-02-09 吴照球 甲氧苄啶的医药新用途
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN112569215A (zh) * 2020-12-30 2021-03-30 东莞市人民医院 度米芬在制备防治结直肠癌的药物中的应用
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (zh) * 2021-06-28 2022-12-30 四川大学 Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (zh) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 五氟利多在制备治疗子宫内膜癌的药物中的应用
CN115887455B (zh) * 2022-08-04 2024-04-05 北京大学人民医院 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用
CN118059099B (zh) * 2024-04-19 2024-06-14 四川大学华西医院 帕罗西汀联合asct2抑制剂用于制备治疗肝癌的药物中的应用及药物组合物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1089583C (zh) * 1993-10-01 2002-08-28 辛泰克斯（美国）公司 霉酚酸2－(4－吗啉代)乙酯高剂量口服悬浮剂
JPH10511655A (ja) * 1994-12-28 1998-11-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗アテローム形成剤としてのネビボロールの使用
ATE449603T1 (de) * 1998-09-15 2009-12-15 Lilly Co Eli Verwendung von duloxetine zur behandlung von fibromyalgie
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
CZ303702B6 (cs) * 2000-07-07 2013-03-20 Trustees Of Tufts College Minocyklinové slouceniny
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20070012618A (ko) * 2003-09-18 2007-01-26 콤비네이토릭스, 인코포레이티드 신생물 치료용 약의 조합
BRPI0416275A (pt) * 2003-11-06 2007-01-23 Celgene Corp métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
WO2005115388A1 (en) * 2004-05-12 2005-12-08 Biorunx Co., Ltd. A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer
EP3138831B1 (en) * 2004-05-21 2020-07-08 President and Fellows of Harvard College Synthesis of tetracyclines and analogues thereof
CN1279980C (zh) * 2004-10-14 2006-10-18 孔庆忠 一种抗实体肿瘤药物组合物
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (zh) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 制备缬沙坦的方法
HUE036189T2 (hu) * 2005-07-28 2018-06-28 Academisch Ziekenhuis Bij De Univ Van Amsterdam Monofenol, benzoldiol vagy szulfhidril vegyületek melanómák kezelésében való alkalmazásra
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
MX2008012061A (es) * 2006-03-23 2008-12-17 Amgen Inc Metodos y composiciones para elaborar y utilizar polimorfos de cinacalcet.
CN101099724A (zh) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 一种微粉化来曲唑及其组合物
CN101103976A (zh) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 一种含阿那曲唑的口服药物组合物及其制备工艺
JP2010515682A (ja) * 2007-01-05 2010-05-13 コーナーストーン セラピューティックス インコーポレイテッド 喘息などの５−リポキシゲナーゼ活性上昇および／またはロイコトリエン活性上昇に関連する状態における使用のためのｒ−ジロートン
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (zh) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂
US20090270397A1 (en) * 2008-04-08 2009-10-29 Orlow Seth J Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (zh) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 氨氯地平在制备治疗细胞增生性疾病药物中的用途
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN101991553B (zh) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 一种依西美坦片及其制备方法
CN101863806B (zh) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 抗前列腺癌药物(r)-比卡鲁胺的制备方法
WO2011146583A2 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
US9018438B2 (en) * 2010-07-29 2015-04-28 Kyoto University Screening method for anticancer drugs
CN103429235A (zh) * 2010-12-15 2013-12-04 赖鸿政 用于治疗癌症的化合物及其应用
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
CN102688493B (zh) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN102813643B (zh) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 bumetanide在抑制肝癌细胞转移中的应用
JP6224597B2 (ja) * 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
WO2013071262A1 (en) * 2011-11-10 2013-05-16 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
ES2384069B1 (es) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet y tumores neuroblásticos
CN102600077B (zh) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 吉西他滨或其盐纳米乳剂注射液及其制备方法
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
WO2014018563A2 (en) 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
US20150224169A1 (en) * 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
KR101839864B1 (ko) * 2012-09-21 2018-03-20 인텐시티 쎄라퓨틱스, 인코포레이티드 암을 치료하는 방법
EP2903616B8 (en) * 2012-10-04 2018-02-07 AB Science Use of masitinib in combination with gemcitabine for treating a subgroup of patients suffering from pancreatic cancer
CN102872066B (zh) * 2012-10-19 2014-07-02 厦门大学 伊维菌素及其衍生物的用途
CA3159085A1 (en) * 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (zh) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 阿那格雷及其衍生物的抗肿瘤用途
CN103396419A (zh) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法
CN103536925B (zh) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN103622975B (zh) * 2013-11-07 2016-06-15 广东药学院 格列吡嗪在制备治疗肿瘤药物中的应用
AU2015243537B2 (en) * 2014-04-08 2020-10-22 The Methodist Hospital INOS-inhibitory compositions and their use as breast cancer therapeutics
ES2973279T3 (es) * 2014-10-24 2024-06-19 Launxp Biomedical Co Ltd Usos de medicamento de duloxetina·HCl en la preparación de una composición farmacéutica para el tratamiento de cáncer

Also Published As

Publication number Publication date
EP3210604A1 (en) 2017-08-30
TWI652060B (zh) 2019-03-01
US20170304388A1 (en) 2017-10-26
EP3222278C0 (en) 2023-06-14
WO2016062274A1 (zh) 2016-04-28
WO2016062278A1 (zh) 2016-04-28
JP2017532351A (ja) 2017-11-02
US10045962B2 (en) 2018-08-14
WO2016062283A1 (zh) 2016-04-28
WO2016062266A1 (zh) 2016-04-28
EP3222278A4 (en) 2018-06-20
AU2015335391B2 (en) 2018-06-21
US10098852B2 (en) 2018-10-16
EP3222278A1 (en) 2017-09-27
CN107106550A (zh) 2017-08-29
KR20170084034A (ko) 2017-07-19
TW201615220A (zh) 2016-05-01
WO2016062287A1 (zh) 2016-04-28
TW201615225A (zh) 2016-05-01
WO2016062272A1 (zh) 2016-04-28
WO2016062270A1 (zh) 2016-04-28
US20170304218A1 (en) 2017-10-26
TW201615196A (zh) 2016-05-01
TW201615184A (zh) 2016-05-01
TW201615192A (zh) 2016-05-01
EP3210604C0 (en) 2024-02-14
TW201615194A (zh) 2016-05-01
TWI672150B (zh) 2019-09-21
EP3222278B1 (en) 2023-06-14
ES2973279T3 (es) 2024-06-19
KR102490334B1 (ko) 2023-01-18
WO2016062285A1 (zh) 2016-04-28
TWI663969B (zh) 2019-07-01
TW201615186A (zh) 2016-05-01
WO2016062290A1 (zh) 2016-04-28
US20170216247A1 (en) 2017-08-03
ES2954860T3 (es) 2023-11-27
US20170304286A1 (en) 2017-10-26
AU2015335375A1 (en) 2017-05-18
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
WO2016062286A1 (zh) 2016-04-28
CN106999470A (zh) 2017-08-01
AU2015335391A1 (en) 2017-06-01
WO2016062281A1 (zh) 2016-04-28
TWI621434B (zh) 2018-04-21
WO2016062269A1 (zh) 2016-04-28
TW201615219A (zh) 2016-05-01
JP6539345B2 (ja) 2019-07-03
WO2016062265A1 (zh) 2016-04-28
TW201615226A (zh) 2016-05-01
WO2016062267A1 (zh) 2016-04-28
EP3235497A1 (en) 2017-10-25
WO2016062279A1 (zh) 2016-04-28
TWI663984B (zh) 2019-07-01
WO2016062291A1 (zh) 2016-04-28
WO2016062275A1 (zh) 2016-04-28
TW201615193A (zh) 2016-05-01
TW201615189A (zh) 2016-05-01
CN107106523A (zh) 2017-08-29
TW201615218A (zh) 2016-05-01
EP3210604A4 (en) 2018-06-27
US20170312260A1 (en) 2017-11-02
AU2015335375B2 (en) 2020-09-10
TW201615188A (zh) 2016-05-01
US20170304387A1 (en) 2017-10-26
TW201615195A (zh) 2016-05-01
WO2016062277A1 (zh) 2016-04-28
TW201615222A (zh) 2016-05-01
EP3210604B1 (en) 2024-02-14
TW201615197A (zh) 2016-05-01
TW201615223A (zh) 2016-05-01
TW201615191A (zh) 2016-05-01
TW201615221A (zh) 2016-05-01
WO2016062289A1 (zh) 2016-04-28
WO2016062288A1 (zh) 2016-04-28
TW201615217A (zh) 2016-05-01
EP3235497A4 (en) 2018-06-13
WO2016062271A1 (zh) 2016-04-28

Similar Documents

Publication Publication Date Title
WO2016062274A1 (zh) 消化系统疾病用药物在制备抑制癌症的医药组合物中的应用
CN104382900A (zh) 治疗放射性肠炎的组合物和方法
CN106361993B (zh) 一种防治胃黏膜损伤的药物组合物及其制备方法
CN102526640B (zh) 一种泮托拉唑钠药物组合物及其制备工艺
CN101534840A (zh) 治疗放射性肠炎的方法
CN101461816B (zh) 柯里拉京的新用途
CN104740112A (zh) 番茄红素和葡萄籽组合物在制备治疗关节炎药物中的应用
CN101036732B (zh) 治疗食道癌的中药制剂及其配制方法
CN105535495A (zh) 一种培元固本治疗食管癌的中药组合物及制备方法
CN106924539B (zh) 一种治疗消化性溃疡、胃炎及反流性食管炎的中药制剂及其制备方法和应用
CN106619745A (zh) 治疗胃肠疾病的生物菌液及其制备方法
CN105726634A (zh) 一种治疗鼻炎病的中药制剂
CN101693084A (zh) 一种治疗胃脘痛阴虚证的药物组合物及其制备方法
CN107335011B (zh) 治疗癌性疼痛的外用中药复方制剂
CN105214067A (zh) 一种治疗结肠癌术后腹泻的药物
CN104784651B (zh) 一种制备用于治疗胃溃疡的药物制剂的方法
CN108939011A (zh) 一种治疗癌症的中草药配方
CN103285326B (zh) 一种治疗胃肠动力障碍的药物组合物
CN105853399A (zh) 百秋李醇在制备治疗慢性胃炎的药物中的应用
CN106421600A (zh) 一种治疗消化道出血的中西药复方制剂及制备方法
Adediran et al. A study of ulcer induced stomach of albino rats treated with idogu mixture, a potent anti-ulcer herbal drug
CN106214977A (zh) 一种治疗噎膈的中药组合物
CN106138919A (zh) 一种治疗胃癌的中药组合物
CN106237245B (zh) 一种治疗急慢性腹泻的中药组合物及其制剂和应用
CN1354002A (zh) 用于治疗胃肠疾病的药物及生产方法